Annexon Biosciences Inc.

ANNX

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

BVF Partners Redmile Group Deerfield Management

Catalysts

No catalysts tracked.

Position Details

BVF PartnersNEWFeb 17, 2026

Shares: 9,128,080Value: $45.8M

# Signal Note: BVF Partners Initiates $45.8M Position in Annexon (ANNX) Mark Lampert's concentrated value fund establishing a ~9.1M share position signals conviction in Annexon's lead asset ANX005, a complement C1q inhibitor in Phase 2 for geographic atrophy (GA). The timing likely reflects upcoming clinical readouts from their GA program, with potential catalysts in late 2024/early 2025 that could validate the complement pathway as differentiated from the currently approved anti-VEGF standard of care.

Redmile GroupNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

STOK3 funds CMPS2 funds IVVD2 funds GPCR2 funds XENE2 funds MIRM2 funds LIVN2 funds COGT

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Redmile Initiates $50.5M Position in ANNX Redmile's new $50.5M stake in Annexon signals conviction in ANX007, a C1q inhibitor targeting complement-driven neuroinflammation across multiple CNS indications including Alzheimer's disease and generalized myasthenia gravis (gMG). The timing likely reflects anticipated near-term catalysts, potentially including Phase 2 data readouts or regulatory updates on its lead programs in 2024-2025. Green's crossover mandate and selective healthcare deployment suggest confidence in valuation and clinical/commercial inflection point ahead.